CN101391001A - 预防高原反应的中药组合物及其制备方法 - Google Patents
预防高原反应的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN101391001A CN101391001A CNA200810107317XA CN200810107317A CN101391001A CN 101391001 A CN101391001 A CN 101391001A CN A200810107317X A CNA200810107317X A CN A200810107317XA CN 200810107317 A CN200810107317 A CN 200810107317A CN 101391001 A CN101391001 A CN 101391001A
- Authority
- CN
- China
- Prior art keywords
- parts
- ethanol
- chinese medicine
- add
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 208000008445 altitude sickness Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 244000124209 Crocus sativus Species 0.000 claims abstract description 21
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 21
- 239000004248 saffron Substances 0.000 claims abstract description 21
- 235000013974 saffron Nutrition 0.000 claims abstract description 21
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 18
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 16
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 241001061264 Astragalus Species 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 210000004233 talus Anatomy 0.000 claims abstract description 6
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 241000208340 Araliaceae Species 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 21
- 241000180649 Panax notoginseng Species 0.000 claims description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000045403 Astragalus propinquus Species 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 241000143437 Aciculosporium take Species 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000008678 sanqi Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 19
- 239000008187 granular material Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 244000132619 red sage Species 0.000 description 12
- 206010021143 Hypoxia Diseases 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 5
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 5
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- -1 knottine Chemical compound 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 2
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- UPCWCCRFMPIOAP-UHFFFAOYSA-N Hydroxytanshinone Chemical compound C1=CC(C(CCC2O)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 UPCWCCRFMPIOAP-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 235000009048 phenolic acids Nutrition 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical class C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- HARGZZNYNSYSGJ-UHFFFAOYSA-N 1,2 dihydrotanshinquinone Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)CO1 HARGZZNYNSYSGJ-UHFFFAOYSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N 6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HARGZZNYNSYSGJ-JTQLQIEISA-N Dihydrotanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2[C@@H](C)CO1 HARGZZNYNSYSGJ-JTQLQIEISA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 description 1
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
预防高原反应的中药组合物及其制备方法,有两种中药组合物:组方1由下列重量份数的原料药制成:人参91-99份、藏红花0.3-1份;组方2由下列重量份数的原料药制成:黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份;本发明药物配比合理、制备工艺精良,携带服用方便,对往返高原人群中普遍发生的高原反应具有很好的预防作用。
Description
技术领域
本发明涉及中药组合物及其制备方法,尤其涉及预防高原反应的中药组合物及其制备方法。
背景技术
高原反应是机体为适应因海拔高造成的气压差、含氧量少、空气干燥等变化而产生的自然生理反应,分为急性高原反应和慢性高原反应两种。现代医学认为高原反应是由于高原大气压和氧分压较低,引起机体的呼吸、循环、消化、血液、泌尿、内分泌以及中枢神经系统等产生不同程度的适应性改变,对于适应良好的人来说,进入高原后很快就能建立起一系列的代偿机制,使各系统机能达到新的动态平衡,对适应不良者,缺氧可使动脉血氧分压和肺泡-动脉血氧分压差降低,出现肺动脉高压,右心室扩大,心肌变性坏死,红细胞增生并激活交感神经,使心率增快。气压低可使细胞肿胀和血管渗透性增强,出现脑水肿、肺水肿、胃黏膜水肿和血压升高等;急性高原反应可呈现不同症状,轻度患者仅有呼吸加快、心跳加速、头晕等感觉,活动不受影响,无需治疗;中度患者有头痛、恶心、呕吐、心慌、气短、胸闷、眼花、失眠、嗜睡、食欲减退、腹胀、腹泻、便秘、口唇发绀、手足发麻等症状,不能参加工作,需要休息并接受对症治疗;重度患者出现呼吸困难、咯血,心跳加速、血压升高、甚至发生抽搐、昏迷和肺水肿,生活不能自理,需吸氧治疗或抢救,其中90%属轻度,8%左右属中度,仅有2%属于重度。
发明内容
本发明的目的是提供能有效预防高原反应的中药组合物及其制备方法。
本发明的目的是这样实现的,预防高原反应的两种中药组合物:
组方1由下列重量份数的原料药制成:人参91-99份、藏红花0.3-1份;
组方2由下列重量份数的原料药制成:黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份;
组方1中人参具有大补元气,补脾益肺,生津,安神之功,《神农本草经》将其列为上品,能“主补五脏,安精神,安魂魄,止惊悸,除邪气,明目开心益智,久服轻身延年”,称其补气之能冠群草。人参的主要成分为人参皂苷和多糖,还含有丰富的氨基酸,维生素,多种矿物质,有机锗及能增强机体特异性免疫力的物质。人参对中枢神经系统具有兴奋作用,能增加脑血流和脑能量代谢,提高脑的摄氧能力;人参能兴奋垂体肾上腺皮质系统,使皮质激素分泌增多,增强机体免疫功能和对各种有害因素的防御能力,提高机体对高原缺氧环境的调节适应能力。
藏红花性平味甘,入心、肝经,具有强烈的活血化瘀和散郁开结的功效,《本草品汇精要》:“主散郁调血,宽胸膈,开胃进饮食,久服滋下元,悦颜色”。
藏红花的主要成分有藏红花酸、藏红花素、藏红花苦素、挥发油、桉脑、蒎烯和多种维生素等。现代药理研究认为藏红花可降低血压,对呼吸有兴奋作用,在低氧条件下提高心肌细胞内乳酸脱氢酶的活性,增强细胞内的氧代谢功能,提高心脏的耐缺氧能力,减弱低氧对心肌细胞的损伤作用。藏红花可抑制血小板的聚集,延长凝血酶原的生成时间和活化时间,提高纤维蛋白酶的活性,降低血液粘度。可提高机体的细胞免疫和体液免疫,调整人体气机运行,增强机体对高原缺氧环境的耐受力。
组方2中黄芪性微温,有补气固表、利永消肿、托毒生肌和补中益气之功效,《神农本草经》中把本品列为上品。黄芪的主要成分是皂甙、黄酮、多糖、氨基酸、亚油酸、生物碱和多种微量元素等。现代研究认为黄芪具有扩张冠状动脉、改善红细胞变形能力,抑制血小板黏附,降低纤维蛋白原及全血比黏度,提高免疫球蛋白,并可通过对单核巨噬细胞、自然杀伤细胞、T细胞、B细胞、细胞因子及神经-内分泌-免疫网络的调节提高机体对高原低氧环境下的耐缺氧能力。
党参味甘、性平,入脾、肺二经,具有补中益气,生津和胃之功效,《本草正义》说:“党参力能补脾健胃,润肺生津,健运中气,本与人参不甚相远”。党参的主要成分为皂甙、多糖、微量生物碱、多种氨基酸(赖氮酸、蛋氨酸、亮氦酸、结氨酸、苯丙氨酸等)以及多种无机元素。现代研究认为党参可增强网状内皮系统的吞噬功能,提高机体的抗病能力,从而使机体达到扶正的作用。党参能提高中枢神经系统的兴奋性和机体的活动能力,提高心排血量而不增加心率,并能增加脑、内脏的血液流量和红细胞、血红蛋白含量,能增强机体的免疫功能。
三七性温,味甘、微苦,人肝、胃、大肠经,具有散瘀止血,消肿定痛的功效,有“止血不留瘀,化瘀不伤正”的美名,为理血的要药。三七的主要成分为三七总皂甙、三七素、黄酮、挥发油、氨基酸、糖类及各种微量元素等。现代研究认为三七具有降低动脉压及略减心律的作用,降低心肌耗氧量;对中枢神经系统具有抑制作用,减少机体的自主活动,降低耗氧量;三七在化学成分上与人参相似,具有人参样的滋补强壮作用,能调节人体免疫功能、使过高或过低的免疫反应恢复到正常,但不干扰机体正常的免疫反应,并能消除疲劳,延缓衰老,增强机体耐缺氧能力。
丹参味苦,性微寒,归心、肝二经,具有祛淤止痛、活血通经、清心除烦之功效。有效成分主要为脂溶性丹参酮类和水溶性酚酸类物质等,丹参酮类包括若干个单体,其中隐丹参酮,二氢丹参酮I、羟丹参酮I-A,丹参酮II-B,丹参甲酯等,其水溶性酚酸类有18种(原儿茶醛、丹参素、原儿茶酸、丹参酸乙、丹参酸丙及丹参酚酸等)。现代研究认为丹参有抗体外血栓形成和抗血小板聚集的功能,对收缩状态的微血管有显著的舒张作用,可改善微循环障碍,改善细胞缺血、缺氧所致的代谢障碍,丹参能明显增加脑血流量,改善能量代谢紊乱和脑水肿,增强机体对缺氧的耐受力。
预防高原反应的中药组合物的制备方法是:
组方1的提取工艺有四种:
a、称取人参91-99份、藏红花0.3-1份,粉碎至20-50目,粉末入药;
b、人参91-99份,参照渗漉法操作,用50%-90%乙醇作溶剂,浸泡1-2周后,进行渗漉,共加入20-40倍量乙醇,合并渗漉液,回收乙醇,浓缩成浸膏;藏红花0.3-1份粉碎入药;
c、人参91-99份,加4-10倍量50%~95%乙醇,共提取2-3次,每次1-3h,合并提取液,回收乙醇,浓缩成浸膏;藏红花0.3-1份粉碎入药;
d、人参91-99份,加水煎煮2-3次,每次1-3h,合并煎液,减压浓缩至相对密度1.0~1.2,加入乙醇,使醇浓度为70%,冷藏,次日减压回收乙醇,浓缩成浸膏;藏红花0.3-1份粉碎入药。
组方2的提取工艺有三种:
a、黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份,各药粉碎过4-8目;
b、黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份,各药粉碎过4-8目,加6-10倍量水,煎煮1-3次,每次1-3h,过滤,合并滤液,浓缩后备用;
c、黄芪30-60份、党参10-40份、丹参10-30份,各药粉碎过4-8目,加6-10倍量80%-95%的乙醇,每次1-3次,每次1-3h,合并滤液,回收乙醇。三七3-10份加8-10倍量50%-65%的乙醇回流提取1-2次,每0.5-2h,合并滤液,回收乙醇后浓缩,备用。
本发明所述的中药组合物可制备为口服液、丸剂、片剂、颗粒剂、胶囊剂、袋泡茶等剂型。
本发明的药物能有效提高机体的调节能力,具有明显的抗缺氧、抗疲劳等作用,为中药预防高原反应的发生提供了可靠的理论依据。
具体实施方式
组方1
实施例1 本发明中药组合物丸剂的制备
取人参91份、藏红花0.5份,参照提取工艺a或b或c或d,加入辅料混合均匀,制成软材,用包衣锅制丸,干燥整粒,包装即得。
实施例2 本发明中药组合物片剂的制备
取人参91份、藏红花0.5份,参照提取工艺a或b或c或d制成的浸膏,加入药用淀粉6g、滑石粉3g、氧化镁3g混匀,干燥,粉碎,过筛整粒,压片即得。
实施例3 本发明中药组合物颗粒剂的制备
取人参91份、藏红花0.5份,参照提取工艺a或b或c或d制成的浸膏,加入辅料混合均匀,制成软材,用制粒机制粒、干燥、整粒,分装于无毒聚氧乙烯塑料包装袋中,装盒即得。
实施例4 本发明中药组合物胶囊剂的制备
取人参91份、藏红花0.5份,参照提取工艺a或b或c或d制成的浸膏,加入辅料混合均匀,经制粒、整粒、低温烘干、装胶囊,打光、分装、灭菌、质检、包装而成。实施例5本发明中药组合物袋泡茶的制备
取人参91份、藏红花0.5份,参照提取工艺a或b或c或d制成的浸膏,低温干燥,粉碎,用40-60目筛过筛,包装成袋泡茶,外包装真空包装。
组方2
实施例1 本发明中药组合物丸剂的制备
取黄芪55份、党参30份、三七5份、丹参30份,参照提取工艺a或b或c,加入辅料混合均匀,制成软材,用包衣锅制丸,干燥整粒,包装即得;
实施例2 本发明中药组合物片剂的制备
取黄芪55份、党参30份、三七5份、丹参30份,参照提取工艺a或b或c制成的浸膏,加入药用淀粉6g、滑石粉3g、氧化镁3g混匀,干燥,粉碎,过筛整粒,压片即得。
实施例3 本发明中药组合物颗粒剂的制备
取黄芪55份、党参30份、三七5份、丹参30份,参照提取工艺a或b或c制成的浸膏,加入辅料混合均匀,制成软材,用制粒机制粒、干燥、整粒,分装于无毒聚氧乙烯塑料包装袋中,装盒即得。
实施例4 本发明中药组合物胶囊剂的制备
取黄芪55份、党参30份、三七5份、丹参30份,参照提取工艺a或b或c制成的浸膏,加入辅料混合均匀,经制粒、整粒、低温烘干、装胶囊,打光、分装、灭菌、质检、包装而成。
实施例5 本发明中药组合物袋泡茶的制备
取黄芪55份、党参30份、三七5份、丹参30份,参照提取工艺a或b或c制成的浸膏,低温干燥,粉碎,用40-60目筛过筛,包装成袋泡茶,外包装真空包装。
临床试验
本发明药品已经临床试验,受测者150例,观察组100例,对照组50例,其中:
观察组:
组方1:男28例,女22例,其中到达3700米以下高原25例,3700-4700米高原15例,4700米以上10例,进入高原前1周开始服药,到高原后继续服药3天,结果显效占60%,有效占30%,无效占10%,加重占0%,总有效率90%。
组方2:男30例,女20例,其中到达3700米以下高原27例,3700-4700米高原14例,4700米以上9例,进入高原前1周开始服药,到高原后继续服药3天,结果显效占55%,有效占25%,无效占20%,加重占0%,总有效率80%。
对照组:男31例,女19例,其中到达3700米以下高原28例,3700-4700米高原16例,4700米以上6例,进入高原前1周开始服药,到高原后继续服药3天,结果高原反应发生率为85%。
药效学试验:
以下通过药效学试验证明本发明药物的有益效果:
1.试验材料
1.1药物
组方1:取人参91份、藏红花0.5份,提取后制成的浸膏,即得。
组方2:黄芪55份、党参30份、三七5份、丹参30份,提取后制成的浸膏,即得。
1.2试剂和仪器
心钠素试剂盒;
低压仓;
血生化测定仪。
1.3动物:SD大鼠,雌雄兼用,体重200-250g,江西中医学院实验动物中心提供。
2.方法与结果
2.1本发明药物颗粒剂对大鼠血氧饱和度和血乳酸含量的影响
取健康SD大鼠36只,雌雄兼用,按体重随机分为3组,对照组、组方1和组方2组,每组12只。受测组在进入低压仓前7天和在低压仓3天给予灌喂药物,对照组灌喂蒸馏水,每日1次。实验结束后即予动脉取血,检测各组大鼠的血氧饱和度和血乳酸含量,结果见表1:
表1:本发明药物颗粒剂对大鼠血氧饱和度和血乳酸的影响(X±S,n=12)
注:与对照组比较,*P<0.05,**P<0.01
2.2本发明药物颗粒剂对大鼠心肺组织心钠素含量的影响
取健康SD大鼠36只,雌雄兼用,按体重随机分为3组,对照组、组方1和组方2组,每组12只。受测组在进入低压仓前7天和在低压仓3天给予灌喂药物,对照组灌喂蒸馏水,每日1次。实验结束后剥离心脏和肺组织,检测各组大鼠心肺组织的心钠素含量,结果见表2:
表2:本发明药物颗粒剂对大鼠心肺组织心钠素含量的影响(X±S,n=12)
注:与对照组比较,*P<0.05,**P<0.01
2.3本发明药物颗粒剂对大鼠游泳时间的影响
取健康SD大鼠36只,雌雄兼用,按体重随机分为3组,对照组、组方1和组方2组,每组12只。受测组在进入低压仓前7天和在低压仓3天给予灌喂药物,对照组灌喂蒸馏水,每日1次。实验结束后将大鼠放入水槽进行游泳试验,水深30cm,水温16度,每只大鼠尾部负重为体重的10%,记录每只大鼠游泳持续时间(自放入水内至头部不能浮出水面10s的时间)。
表3:本发明药物颗粒剂对大鼠游泳时间的影响(X±S,n=12)
注:与对照组比较,*P<0.05,**P<0.01
3.结论
本发明药物组方1和组方2皆能提高大鼠的血氧饱和度和心肺组织的心钠素含量、降低大鼠血乳酸含量、延长大鼠的负重游泳时间,其中以组方1的效果最好。
上述药效学试验表明:本发明药物能有效提高机体的调节能力,具有明显的抗缺氧、抗疲劳等作用,为中药预防高原反应的发生提供了可靠的理论依据。
Claims (4)
1、一种预防高原反应的中药组合物,其特征在于:它由下列重量份数的原料药制成:人参91-99份、藏红花0.3-1份。
2、一种预防高原反应的中药组合物,其特征在于:它由下列重量份数的原料药制成:黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份
3、一种权利要求1所述的预防高原反应的中药组合物的制备方法,其提取工艺方法有四种:
a、称取人参91-99份、藏红花0.3-1份,粉碎至20-50目,粉末入药;
b、人参91-99份,参照渗漉法操作,用50%-90%乙醇作溶剂,浸泡1-2周后,进行渗漉,共加入20-40倍量乙醇,合并渗漉液,回收乙醇,浓缩成浸膏;藏红花0.3-1份粉碎入药;
c、人参91-99份,加4-10倍量50%~95%乙醇,共提取2-3次,每次1-3h,合并提取液,回收乙醇,浓缩成浸膏;藏红花0.3-1份粉碎入药;
d、人参91-99份,加水煎煮2-3次,每次1-3h,合并煎液,减压浓缩至相对密度1.0~1.2,加入乙醇,使醇浓度为70%,冷藏,次日减压回收乙醇,浓缩成浸膏;藏红花0.3-1份粉碎入药。
4、一种权利要求2所述的预防高原反应的中药组合物的制备方法,其提取工艺方法有三种:
a、黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份,各药粉碎过4-8目;
b、黄芪30-60份、党参10-40份、三七2-6份、丹参10-30份,各药粉碎过4-8目,加6-10倍量水,煎煮1-3次,每次1-3h,过滤,合并滤液,浓缩后备用;
c、黄芪30-60份、党参10-40份、丹参10-30份,各药粉碎过4-8目,加6-10倍量80%-95%的乙醇,每次1-3次,每次1-3h,合并滤液,回收乙醇。三七3-10份加8-10倍量50%-65%的乙醇回流提取1-2次,每0.5-2h,合并滤液,回收乙醇后浓缩,备用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810107317XA CN101391001A (zh) | 2008-10-30 | 2008-10-30 | 预防高原反应的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810107317XA CN101391001A (zh) | 2008-10-30 | 2008-10-30 | 预防高原反应的中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101391001A true CN101391001A (zh) | 2009-03-25 |
Family
ID=40491642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810107317XA Pending CN101391001A (zh) | 2008-10-30 | 2008-10-30 | 预防高原反应的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101391001A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107536919A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种治疗和/或预防胃神经官能症的中药组合物、其制备方法及用途 |
| CN114159488A (zh) * | 2021-12-30 | 2022-03-11 | 辽宁上药好护士药业(集团)有限公司 | 一种药物组合物及其在提高缺氧耐受力领域的应用 |
| CN116585418A (zh) * | 2023-03-28 | 2023-08-15 | 中国人民解放军总医院第六医学中心 | 一种预防高原反应的中药制备工艺 |
| CN117652664A (zh) * | 2024-01-02 | 2024-03-08 | 广州能靓生物技术有限公司 | 促进血液循环、缓解手脚冰凉及抗疲劳的组合物及其应用 |
-
2008
- 2008-10-30 CN CNA200810107317XA patent/CN101391001A/zh active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107536919A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种治疗和/或预防胃神经官能症的中药组合物、其制备方法及用途 |
| CN107536918A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种治疗和/或预防心脏神经官能症的中药组合物、其制备方法及用途 |
| CN107535790A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种西红花人参颗粒饮品、其制备方法和应用 |
| CN107536920A (zh) * | 2016-06-23 | 2018-01-05 | 上海医药集团股份有限公司 | 一种治疗周围神经炎的组合物、其制备方法和应用 |
| CN114159488A (zh) * | 2021-12-30 | 2022-03-11 | 辽宁上药好护士药业(集团)有限公司 | 一种药物组合物及其在提高缺氧耐受力领域的应用 |
| CN116585418A (zh) * | 2023-03-28 | 2023-08-15 | 中国人民解放军总医院第六医学中心 | 一种预防高原反应的中药制备工艺 |
| CN117652664A (zh) * | 2024-01-02 | 2024-03-08 | 广州能靓生物技术有限公司 | 促进血液循环、缓解手脚冰凉及抗疲劳的组合物及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716240A (zh) | 一种用于改善睡眠、补气生血的制剂 | |
| CN103520577A (zh) | 一种治疗尘肺、清肺养心的药食两用制剂及其制备方法 | |
| CN103877263A (zh) | 一种红参、玛咖、绿茶提取物(茶氨酸)等复合中药抗疲劳养生制剂 | |
| CN101524469B (zh) | 一种治疗充血性心力衰竭的中药复方制剂及其制备方法 | |
| CN103007215A (zh) | 一种治疗水肿的中药组合物 | |
| CN104758806A (zh) | 一种治疗冠心病的煎膏剂及其制备方法 | |
| CN101999663A (zh) | 中药组合物在制备缓解体力疲劳保健食品及药品中的应用 | |
| CN100473413C (zh) | 一种治疗老年期痴呆的中药制剂 | |
| CN101391001A (zh) | 预防高原反应的中药组合物及其制备方法 | |
| CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
| CN101073333A (zh) | 多味解乏饼干 | |
| CN109718303A (zh) | 提高女性卵巢功能养颜美容改善女性皮肤的中药组合物 | |
| CN105343466A (zh) | 一种治疗冠心病的中药组合物 | |
| CN104274808A (zh) | 抗高原反应的中药组合物 | |
| CN102258628A (zh) | 一种具有促进排铅作用的中药组合物 | |
| CN102134550A (zh) | 一种保健补酒及其制备工艺 | |
| CN101675983A (zh) | 气虚症温补剂 | |
| CN104940516B (zh) | 一种治疗慢性再生障碍性贫血的中药组合物及其制备方法与应用 | |
| CN104825777A (zh) | 一种具有补气安神功效的保健胶囊及制备方法 | |
| CN104983759A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
| CN112402569A (zh) | 一种抗疲劳保健品及其制备方法 | |
| CN104857121A (zh) | 一种治疗高血脂症的药物组合物及其应用 | |
| CN105168581A (zh) | 一种中药组合物用于制备治疗糖尿病肾病药物中的用途 | |
| CN109718304A (zh) | 改善人体心脑血管功能微循环及预防血栓的中药组合物 | |
| CN100515462C (zh) | 治疗心、脑血栓性疾病的中药及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090325 |